Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
SGN 0.245 −3.9% CNC 1.47 +0.0% PHNM 0.325 +0.0% LIO 0.150 −6.2% RIO 2.71 −2.9% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.56 +3.3% ALTA 0.175 +0.0% CLCH 1.10 +5.8% SCOT 2.09 −0.9% VCT 0.060 +0.0% BOL 0.070 −6.7% MCM 0.300 +0.0% SYH 0.410 −4.7% LGO 0.930 +0.0% SGN 0.245 −3.9% CNC 1.47 +0.0% PHNM 0.325 +0.0% LIO 0.150 −6.2% RIO 2.71 −2.9% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.56 +3.3% ALTA 0.175 +0.0% CLCH 1.10 +5.8% SCOT 2.09 −0.9% VCT 0.060 +0.0% BOL 0.070 −6.7% MCM 0.300 +0.0% SYH 0.410 −4.7% LGO 0.930 +0.0%
Financings

Lobe Sciences Announces the Closing of the Previously Announced Private Placement

By The Northwire Desk — AI Analysis Aug 14, 2025 · 23:00 LOBE · 0.055 Lobe Sciences Ltd.
LOBE · Price

Executive Summary

  • Lobe Sciences Ltd. announces the closing of a non-brokered private placement of up to 8,535,625 common shares.
  • The shares were priced at $0.04 per share, generating gross proceeds of up to $341,425 CAD.
  • This offering was previously announced on July 29, 2025, and securities are subject to a statutory hold period.

Key Details

  • Transaction Type: Closing of non-brokered private placement.
  • Quantity: Up to 8,535,625 common shares.
  • Price: $0.04 per share.
  • Gross Proceeds: Up to $341,425 CAD.
  • Hold Period: Securities are subject to a statutory four-month and one-day hold period.
  • Regulatory Status: Securities were not registered under the US Securities Act of 1933 and are not offered or sold in the United States.
  • Previous Announcement: The offering was initially announced on July 29, 2025.
Read the original news release →

More from Lobe Sciences Ltd.

Jun 09, 2026 · 06:00

Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares

Other Jun 01, 2026 · 22:00

Lobe Sciences Settles $1.37M Debt with Equity, Advances L-130 and S-100 Clinical Programs

Financings May 06, 2026 · 06:00

Lobe Sciences Secures Funding But Burn Rate Accelerates Amidst Clinical Progress

Earnings Apr 23, 2026 · 08:00

Balance Sheet Restructuring and Regulatory Tailwinds Support Pipeline Progress

Regulatory Apr 20, 2026 · 06:00

Lobe Sciences Secures Funding for Sickle Cell Candidate Amid Balance Sheet Strengthening

Financings Apr 10, 2026 · 20:00

Lobe Sciences Secures Runway with Modest Financing Amidst Strong Balance Sheet

Financings